Report Store Get Proposal

Home Blog Oncology 2

Oncology

medtech-news-for-rongtao-medical-nipro-lyric-health

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Rongtao Medical Receives Prestigious Bonded Repair Authorization for Ultrasound in China; NIPRO Introduces ELISIO™-HX Expanded Hemodialysis System to U.S. Market Following FDA Clearance; Lyric Health Unveils Asynchronous Care Solution for Smarter, Connected Virtual Care; New England Biolab® Strengthens Cell-Free RNA Workflow with Monarch® Mag Cell-free RNA Extraction Kit; Aqua Medical Advances Type 2 Diabetes Research with First U.S. Patient Treated at UNC Health; MediView XR90™ Holographic Surgical Navigation System Debuts in Florida at Cleveland Clinic Weston Hospital

Rongtao Medical Wins Bonded Repair Approval as One of the First in China for Ultrasound On 05 August 2026, Rongtao Medical received regulatory approval to conduct bonded repair services for imported ultrasound systems, becoming one of the earliest companies in China to obtain this qualification. The approval marked a significant advancement in the country's medical device servicing capabilities by allowing ultrasound equipment to be repaired within bonded zones under an authorized framework. This development was expected to improve repair efficiency, shorten equipment downtime, and reduce maintenance expenses for healthcare institutions. The milestone also re...

Explore More...

sanofi-sarclisa-escena-approval

Sanofi’s SARCLISA ESCENA Makes History as the First Wearable Cancer Treatment

drug-approvals-in-h2-2026

Top FDA Approvals to Watch in H2 2026: Regulatory Decisions Poised to Transform the Pharmaceutical Landscape

rise-of-targeted-therapeutics

The Rise of Targeted Therapeutics in Modern Healthcare

pharma-news-for-hengrui-kailera-gsk

Hengrui Pharma Encounters FDA Regulatory Hurdle for Camrelizumab–Rivoceranib; Kailera Therapeutics Announces Positive Results for HRS-7535/KAI-7535 Across Two Phase 3 Studies; Jemperli Underscores Durable Clinical Complete Responses in dMMR/MSI-H Rectal Cancer; FDA Approves PADCEV-Keytruda Combination for Neoadjuvant and Adjuvant Treatment of Muscle-Invasive Bladder Cancer; Sanofi’s Subcutaneous Sarclisa Escena Gains US Approval

pharma-news-for-novartis-roche-otsuka

Novartis to Acquire Myricx Bio; Roche’s Divarasib Tops Approved KRAS G12C Inhibitors in Phase III NSCLC Trial; Otsuka Reports Positive Two-Year Phase 3 Results for VOYXACT in IgA Nephropathy; Revolution Medicines Reports Early Clinical Data for Zoldonrasib Combination Regimens at ESMO GI 2026; Can-Fite Completes Patient Enrolment for Interim Analysis in Pivotal Phase 3 Psoriasis Trial

pcpg-therapeutic-landscape

Paragangliomas and Pheochromocytomas Treatment Space Steps into the Precision Therapy Era

progeria-causes-symptoms-risk-factors-and-treatment-options

Progeria Syndrome: The Rarest Case of Premature Ageing

pharma-news-for-zymeworks-ipsen-viridian-assessment

Zymeworks Announces Acquisition of Theravance Biopharma; Ipsen to Acquire Kartos Therapeutics; Viridian Therapeutics Wins U.S. FDA Approval for Lumvoa; Replimune Reaches FDA Milestone with RP1 BLA Resubmission Acceptance; Epicrispr Announces Encouraging Clinical Data for EPI-321 in FSHD

trodelvy-approval-for-mtnbc

TRODELVY’s First-Line TNBC Approval: Gilead’s Big Bet Reshapes the TROP2 ADC Battlefield

role-of-fusion-biopsy-in-prostate-cancer-detection

Fusion Biopsy: The Next Generation of Prostate Cancer Detection

next-frontier-in-egfr-mutant-nsclc-treatment

EGFR-Mutant NSCLC: From Targeted Therapy Breakthroughs to the Next Era of Precision Medicine

evolution-of-biliary-tract-cancer-treatment

Navigating the Future of Biliary Tract Cancer Treatment: Precision Oncology and Emerging Therapeutic Strategies

pharma-news-for-astrazeneca-merck-jazz

Ultomiris Receives US Priority Review for Adult IgA Nephropathy Treatment; FDA Approves WELIREG Plus KEYTRUDA or KEYTRUDA QLEX for Adjuvant Treatment of Select ccRCC Patients; Jazz Pharmaceuticals Highlights Phase 3 LAGOON Trial Update for Zepzelca® in Second-Line SCLC; Novartis’ delpacibart braxlosiran (del-brax) Achieves Primary Biomarker Endpoint in Phase I/II FSHD Study; Takeda’s Zasocitinib Tops Deucravacitinib in Phase 3 Psoriasis Trial, Setting a New Benchmark for Oral Therapies; IMAAVY Demonstrates Clinically Meaningful and Sustained Hemoglobin Responses in Pivotal wAIHA Study

pfizers-oncology-leadership-strategy

From Seagen to Innovent: Inside Pfizer’s Playbook for Oncology Leadership

pharma-news-for-roche-incyte-tango

Roche Expands Pipeline Through Global Bexobrutideg Partnership with Nurix Therapeutics; Incyte to Acquire Vega Therapeutics; Tango Therapeutics Unveils Promising Pancreatic Cancer Data with Vopimetostat–Daraxonrasib Combination; Otsuka Announces Encouraging 12-Month eGFR Outcomes from Phase 3 VISIONARY Study of VOYXACT in IgAN; Innovent Biologics Unveils Phase 3 DREAMS-3 Findings for First Approved GCG/GLP-1 Dual Receptor Agonist

rise-of-oral-serds

Oral SERDs Defy the Odds Amid a History of Pipeline Setbacks

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly